Two-drug treatment for negative symptoms of schizophrenia
Treatments studied
Part of Mental health clinical trials.
This trial tests two medicines, deferiprone and N-acetylcysteine, taken together to see if they improve negative symptoms of schizophrenia, such as lack of motivation or pleasure. It aims to find a new option for people who still have these symptoms despite their current antipsychotic treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Between 18 and 55 years old
- Diagnosed with schizophrenia or schizoaffective disorder
- On the same antipsychotic medicine for at least 2 months before starting
- Have had negative symptoms for at least 6 months
- Have a support person (like a family member or nurse) who can help with taking medicine
- Able to have an MRI scan and not have certain health conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called roluperidone for people with schizophrenia who have ongoing negative symptoms (like low motivation or social withdrawal) but stable positive symptoms (like hallucinations). It aims to see if the drug helps with these symptoms and if it can reduce the chance of relapse compared to other medications.
This study tests whether a medication that boosts brain NMDA receptors can improve negative symptoms in schizophrenia, and looks at differences between men and women. It is for people with stable schizophrenia who still have mostly flat mood or low motivation.
This trial tests a combination of an NMDA-targeting medicine and an anti-inflammatory treatment for people with schizophrenia that has not responded well to several standard treatments, including clozapine. If you qualify, the goal is to see whether this combination improves symptoms more than usual care.
This trial tests if a supplement called PQQ can help with cognitive problems and negative symptoms (like lack of motivation) in people with schizophrenia. It may offer a new way to support current treatment.
This Phase 2 study tests an NMDA-enhancer medicine to see if it can help people who are in the early “prodromal” stage—when symptoms are starting but full schizophrenia is not diagnosed yet. It aims to reduce or prevent worsening symptoms over the study period.
This trial tests an experimental combination treatment that targets two different brain receptors (sigma-1 and NMDA) to see if it can improve symptoms in people with schizophrenia that hasn't responded well to standard antipsychotics.
Hear when a new Schizoaffecitve Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.